Clinical Trials Logo

Clinical Trial Summary

Stenosis is one of the most frequent complications in patients with Crohn's disease (CD). In particular, CD patients with multi segmental intestinal strictures are often faced with short bowel syndrome after repeated or extensive surgical resection. Strictureplasty conserves bowel and minimizes the risk of developing short-bowel syndrome in the short-term and, probably, long-term. Strictureplasty has become an established surgical option in the management of obstructive Crohn's disease, especially for multiple short fibrous strictures. It is particularly suitable for patients at risk for short-bowel syndrome. Endoscopic management shows good efficacy and safety in the treatment of strictures in CD patients. The ECCO guideline recommended that endoscopic balloon dilatation is suitable to treat short [<5 cm] strictures of the terminal ileum in CD. Recently, Lan et al. reported that endoscopic stricturotomy appeared to be more effective in treating CD patients with anastomotic stricture than endoscopic balloon dilatation. However, there is no scientific evidence for determining the most appropriate treatment for multiple fibrosis stenosis. We designed a prospective randomized comparative study of the treatment of multisegmental fibrostenosing Crohn's disease (surgical resection plus endoscopic stricturotomy versus surgical resection plus strictureplasty).

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT04865484
Study type Interventional
Source Sixth Affiliated Hospital, Sun Yat-sen University
Contact Qin Guo, MD
Phone +86-20-38663423
Email [email protected]
Status Recruiting
Phase N/A
Start date March 12, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04046913 - The ADDapt Diet in Reducing Crohn's Disease Inflammation N/A
Withdrawn NCT04349449 - ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
Active, not recruiting NCT03058679 - Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease N/A
Completed NCT02871635 - BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity Phase 3
Recruiting NCT04266600 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease N/A
Recruiting NCT04539665 - Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease. N/A
Recruiting NCT03913572 - Treatment of Perianal Disease Using Adipose-derived Stem Cells
Recruiting NCT03606499 - Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
Completed NCT03668249 - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Recruiting NCT04102111 - A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease Phase 2
Not yet recruiting NCT04398836 - Preoperative Nutrition for Crohn's Disease Patients Phase 3
Not yet recruiting NCT04502303 - 18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease Phase 2
Not yet recruiting NCT02878395 - Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases N/A
Withdrawn NCT02820493 - Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF Phase 4
Recruiting NCT02332356 - Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease Phase 3
Completed NCT02161640 - Vascular Dysfunction in Paediatric IBD N/A
Completed NCT00999115 - Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn`s Disease (ALOREVA) Phase 1/Phase 2
Completed NCT00521950 - Cost-effectiveness of TPMT Pharmacogenetics N/A
Recruiting NCT00383344 - Use of FDG PET/CT to Evaluate Crohn Disease Phase 2
Completed NCT00206674 - Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease Phase 3